Equity · Healthcare
COGT
NASDAQCogent Biosciences, Inc.
The line runs $37.48 on 13 July through $31 on 9 October, on a scale from $25 to $45. Days the market did not trade hold the previous close, flat.
as of Oct 9, 2026
COGT insider trades
COGT has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 1 October 2025.
Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
COGT reported financials
SEC EDGARCOGT reported net income of −$328.9M for the fiscal year ended 31 Dec 2025.
COGT earnings
no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
COGT institutional holders
SEC EDGAR11 of the 45 institutional funds we track reported a COGT position for the quarter ended 30 Jun 2026 — a combined $261.9M; the latest of those filings landed 02 Sep 2026.
Showing the 10 largest of 11 reported positions. The figures above count all of them.
COGT fails-to-deliver
SECOn 31 Aug 2026, 2,363 shares of COGT failed to deliver (about $82K) — the latest of at least 3 consecutive trading days with recorded fails. The run reaches the start of the window we read, so it may have begun earlier.
Congressional trades in COGT
House disclosuresThe most recent congressional trade disclosed in COGT is a purchase by Sara Jacobs (house, CA), dated 12 Dec 2022.
Sources
- Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
- SEC EDGARSEC EDGAR 13F filings
- SECSEC fails-to-deliver (CNS) data
- House disclosuresU.S. House of Representatives financial disclosures
- SEC EDGARValuation computed from SEC EDGAR filings